Sunnylands initiative for an HIV cure

Sharon R Lewin AO, FRACP PhD FAHMS
Co-chair, Scientific Advisory Board, IAS
Towards a Cure
The Annenberg Trust at Sunnylands is an independent nonpartisan, nonprofit organization dedicated to convening global leaders in the public and private sectors to promote world peace, facilitate international agreement, and seek solutions to the most daunting challenges facing the world today.
• **Host:** IAS in partnership with the Annenberg Trust at Sunnylands

• **Objective:** To consider what it will take to develop and ensure the widest possible access to a cure for HIV, specifically in sub-Saharan Africa.

• **Goals:**
  – To align on a **Target Product Profile** for an HIV Cure
  – To agree what it will take to ensure that a cure with this profile is **widely accessible** to the **largest number** of people in sub-Saharan Africa.
Who was there?

- **Science**
  - Françoise Barré-Sinoussi
  - Steve Deeks
  - Sharon Lewin
  - Thumi Ndung’u
  - Linda-Gail Bekker
  - Izukanji Sikazwe
  - Yiming Shao

- **Funders**
  - NIH (Maureen Goodenow, Diana Finzi)
  - ANRS (François Dabis)
  - amfAR (Rowena Johnston)
  - BMGF (Mike McCune)
  - Jack Whitescarver

- **Community**
  - Moses Supercharger

- **Industry**
  - Gilead (Gregg Alton)
  - Viiv (John Pottage)
  - Merck (Daria Hazuda)
  - Novartis (Gary Nabel)

- **HIV Programs (Africa)**
  - Peter Cherutich (Kenya)
  - Sani Aliyu (Nigeria)

- **Global Leadership**
  - Mark Dybul
  - Eric Goosby
  - Elhadj As Sy (Red Cross)

- **African Leadership**
  - Jay Varma (Africa CDC)

- **NGOs**
  - Mark Feinberg (IAVI)
  - Mitchell Warren (AVAC)
  - David Ripin (CHAI)
  - George Jagoe (MMV)
  - Ram Prasad (Final Mile)

- **Sunnylands Foundation**
  - David Lane
  - Rob Fallon
  - Ellen LaPointe
  - Wendy Wertheimer
What we discussed?
Current and future landscape for HIV

- cART
- Long-acting ART
- Broadly neutralizing antibodies
- First generation
- Second generation
- Third generation
- Single shot cure

We are here

Daily treatment modalities

Long acting treatment modalities

Cure modalities

2019 20?? 20?? 20?? 20??
Target populations to consider

- Suppressed on ART
- Viremic on ART
- Diagnosed not treated
- Not diagnosed
- At risk
Target Product Profile (TPP)

- Help to align **all stakeholders by broadly defining the regimen or product** the community wants to deliver to the field

- Form the “**north star**” and define the **minimally-acceptable and optimistic interventions**

- Will evolve based on **breakthrough scientific developments** and changing **patient needs**
## What a TPP might look like

<table>
<thead>
<tr>
<th>indication</th>
<th>clinical effect</th>
<th>primary delivery channel</th>
<th>special populations</th>
</tr>
</thead>
<tbody>
<tr>
<td>contraindications</td>
<td>re-exposure, re-use</td>
<td>follow-up</td>
<td>companion diagnostic</td>
</tr>
<tr>
<td>target population</td>
<td>safety, toxicity</td>
<td>registration path</td>
<td>cost of goods sold</td>
</tr>
<tr>
<td>target settings</td>
<td>Dosing, administration</td>
<td>storage, handling</td>
<td>financing source</td>
</tr>
</tbody>
</table>
Towards a public private partnership for an HIV Cure

A platform for driving coordinating progress towards the goal of an HIV Cure

- R&D Community
- Regulatory & Normative Standards
- Financing Organizations
- Implementers
- Community Members

- Owns TPPs and drives alignment across HIV Cure stakeholders
- Small secretariat drives communication and coordinates with relevant organizations
- Lean organizational structure with ability to evolve to changing needs over time
- Learn from other successful Public Private Partnerships such as MMV
Target Product Profile working group

• Co-chaired by Dr. Sharon Lewin and Dr. Steven Deeks and includes leaders from the pharmaceutical industry, research institutions, advocacy groups, and potential funders

• Develop TPPs for HIV cure, including those applicable to LMICs and other resource-constrained settings

• To broadly share TPPs for input, including community, end users, funders
HIV Cure Acceleration for Africa (HCAAP) working group

- Co-chaired by Dr. Izukanji Sikazwe and Dr. Mark Dybul, and includes leaders from across R&D, regulatory, implementers, civil society, and potential funders
- Accelerate and influence the design of cure products to maximize implementation
- Sensitize key stakeholders to promote rapid uptake of products

HCAAP is a public private partnership established to drive and coordinate end-to-end progress towards the goal of an HIV cure across all relevant stakeholders
Next steps and timelines

**TPP WG timeline**

- **July – September 2019**: Categorize and draft initial TPPs, including minimum and optimum targets
- **September – December 2019**: Socialize TPPs more broadly, with HCAAP
- **January – February 2020**: Conduct Delphi exercise to finalize TPPs
- **Q1-2 2020**: Publish TPPs and determine long-term maintenance strategy

**HCAAP timeline**

- **July 2019**: Share first draft concept note – with working group (in progress)
- **July - September 2019**: Consider a face to face meeting of HCAAP
- **December 2019**: Socialize HCAAP at ICASA 2019; publish finalized HCAAP concept note
- **Q1-2 2020**: seek funding for HCAAP
Acknowledgements

- Bill & Melinda Gates Foundation
  - Cathy Bansbach
  - Timothy Attoye
  - Adam Jiang
  - Mike McCune

- International AIDS Society
  - Rosanne Lamplough
  - Roger Tatoud

- The Annenberg Foundation Trust at Sunnylands
  - Rob Fallon
  - David Lane

- McKinsey & Company
  - Matt Craven
  - Matt Wilson

- Sunnylands working group
  - Mark Dybul
  - Rosanne Lamplough
  - Ellen LaPointe
  - Sharon Lewin
  - Steve Deeks
  - Mike McCune
  - Joe Tucker
  - Wendy Wertheimer